CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 307 enrolled
Drug / intervention
Nivolumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02327078
NCT02327078Phase 2Completed
CompareCT.gov

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation·interventional·Posted Dec 30, 2014·Updated Aug 14, 2025

In Brief

A Phase 2 clinical trial evaluating Nivolumab, Epacadostat, and 1 other intervention for B-cell Malignancies and 7 related conditions. Completed, enrolled 307 participants across 24 sites in 2 countries.

Detailed Summary

This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors and lymphomas. Part 2 will evaluate the safety and tolerability of epacadostat in combination with nivolumab and chemotherapy in subjects with squamous cell carcinoma of head and neck (SCCHN) and non-small cell lung cancer (NSCLC). Phase 2 will include expansion cohorts in 7 tumor types, including melanoma, NSCLC, SCCHN, colorectal cancer, ovarian cancer, glioblastoma and diffuse large B-cell lymphoma (DLBCL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma
CountriesUnited Kingdom, United States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 30, 2014
Enrollment StartNov 26, 2014
Primary CompletionJun 16, 2020
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 11.5 years ago

Interventions

Nivolumabdrug

specified dose and dosing schedule

Epacadostatdrug

oral twice daily continuous at the protocol-defined dose

Chemotherapydrug

Specified dose on specified days